Neuropeptide Y potentiation of potassium-induced noradrenaline release in the hypothalamic paraventricular nucleus of the rat in vivo.
NPY is co-localised with catecholamines in the brain and periphery. Noradrenaline and NPY are present in high concentrations in the PVN of the hypothalamus, an area implicated in autonomic regulation. This microdialysis study examined whether NPY can modulate rat PVN noradrenaline release in vivo, as has been shown in vitro. Basal and K(+)-stimulated noradrenaline release was measured after i.c.v. administration of 2 nmol NPY or vehicle. No effect of NPY was observed on basal release, however a significant doubling of K(+)-induced release was observed, both 60 and 150 min following i.c.v. NPY. This raises the possibility that NPY may potentiate rather than inhibit brain noradrenaline release in vivo.
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000704:Analysis of Variance; D000818:Animals; D001481:Basal Metabolism; D004357:Drug Synergism; D006719:Homovanillic Acid / Q000378:metabolism; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D008297:Male; D017551:Microdialysis; D009478:Neuropeptide Y / Q000494:pharmacology*; D009638:Norepinephrine / Q000378:metabolism*; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects* / Q000378:metabolism; D011188:Potassium / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013268:Stimulation, Chemical
D009478:Neuropeptide Y; D015102:3,4-Dihydroxyphenylacetic Acid; D006897:Hydroxyindoleacetic Acid; D011188:Potassium; D009638:Norepinephrine; D006719:Homovanillic Acid